News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hyperion Therapeutics To Report Second Quarter 2014 Financial Results After Market On August, 7, 2014



8/4/2014 8:27:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRISBANE, Calif., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report second quarter 2014 financial results after market close on Thursday, August 7, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

A live and subsequently archived audio webcast of the conference call can be accessed on Hyperion's investor relations website at: http://investors.hyperiontx.com/events.cfm.

To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787 International and use the conference ID# 77704920. A replay of the call will be available for seven days by accessing Hyperion's investor relations website or by dialing 855-859-2056 U.S. or (404) 537-3406 International and use conference ID# 77704920 beginning approximately one hour after the conference call concludes.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. In addition, the company is developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy and DiaPep277, a first-in-class immunotherapy for the potential treatment of new onset Type 1 diabetes. For more information, please visit www.hyperiontx.com.

CONTACT: Myesha Edwards Corporate Communications and Investor Relations (650) 745-7829

Hyperion Logo

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES